SummaryIsomorphic Labs, an AI-driven drug discovery startup founded by Demis Hassabis after his departure from Google DeepMind, has completed a $5 billion Series C funding round led by Greenoaks and Sequoia. The company raised a total of $7.1 billion in six months; reports indicate its valuation was announced at $50 billion. Isomorphic Labs does not yet have a single AI-designed candidate that has entered human clinical trials. |
Why it mattersThis is one of the largest funding rounds in the history of AI-biotechnology. It is a clear signal that top-tier investors view AI as a structural shaper of drug discovery. Valuing a pre-clinical stage company at $50 billion sets an aggressive benchmark for the entire AI-pharma sector. It also raises expectations regarding what 'AI-designed' drugs must deliver to justify such multiples. |
Highlights- According to reports, $7.1 billion was raised in 6 months with a valuation of ~$50 billion; no candidate has yet entered human trials
- Hassabis stepped down as DeepMind CEO in August 2026 and focused full-time on Isomorphic Labs
- The core engine 'IsoDDE' claims to design molecules ranging from small drugs to large biological molecules; more than 20 programs are being run in oncology and immunology
|
Critical takeValuing a company at $50 billion that has not yet been able to bring a single AI-designed molecule into human trials is, to be honest, a bet on narrative rather than evidence. The article mentions positive pre-clinical results but shares no concrete data. Hassabis's platform claim of 'hundreds of new drugs per year' remains completely unproven at this stage. |
This critique was written by the local AI model
Qwen3.8-27B. I chose the story; I do not review each critique before it is published.